Johnson & Johnson

Equities

JNJ

US4781601046

Pharmaceuticals

Market Closed - Nyse 21:00:02 14/06/2024 BST 5-day change 1st Jan Change
145.5 USD +0.06% Intraday chart for Johnson & Johnson -1.05% -7.15%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Johnson & Johnson Announces Late-Breaking Results Show nipocalimab Significantly Improves Sjögren's Disease Activity in A Phase 2 Study CI
EU regulator mandates label updates on CAR-T cancer therapies RE
J&J: encouraging trial in relapsing multiple myeloma CF
J&J: the promise of ibrutinib in CLL CF
J&J: promising results for Imbruvica in leukemia CF
Johnson & Johnson Reports Positive Long-Term Results for Talvey in Multiple Myeloma Study MT
Johnson & Johnson Announces TALVEY® (Talquetamab-Tgvs) Demonstrates Highly Durable, Longer-Term Responses in Patients with Relapsed or Refractory Multiple Myeloma CI
High-risk health workers can get routine Ebola vaccine, Gavi says RE
Xencor to Regain Exclusive Global Rights to CD20 x CD3 Bispecific T-Cell Engager MT
Xencor : J&J's Janssen Termintates Rights to Plamotamab DJ
High-risk health workers can get routine Ebola vaccine, says Gavi RE
Transcript : Johnson & Johnson Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 02:00 PM
Cancer victims ask court to block J&J talc bankruptcy RE
Sector Update: Health Care Stocks Softer Late Afternoon MT
Sector Update: Health Care MT
Johnson and Johnson Talcum-Settlement Consent Judgments Filed -- Update DJ
Johnson & Johnson to Pay $700 Million in Talc Case Settlement With 43 State Prosecutors MT
J&J Talcum-Settlement Consent Judgments Filed, U.S. State AGs Say DJ
RTW Biotech portfolio company to sell subsidiary for USD1.25 billion AN
Top law firms in US opioid lawsuits to get hundreds of millions in fees RE
J&J-backed Rapport Therapeutics shares debut nearly 6% higher RE
J&J: FDA approves VELYS for knee arthroplasty CF
AbbVie's tight grip on Humira market raises concerns about biosimilars RE
J&J-backed Rapport Therapeutics raises $136 mln in US IPO RE
Citigroup Adjusts Price Target on Johnson & Johnson to $180 From $185, Keeps Buy Rating MT
Chart Johnson & Johnson
More charts
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals; - consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc. At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25). Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
145.5 USD
Average target price
171.7 USD
Spread / Average Target
+17.99%
Consensus
  1. Stock Market
  2. Equities
  3. JNJ Stock
  4. News Johnson & Johnson
  5. Johnson & Johnson Allegedly Engaged in 'Bad Faith' Bankruptcies That Harm Talc Victims, Lawsuit Says
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW